Roche's FDA Approved Zelboraf Fights War Against Melanoma Gene Variant
8/18/2011
Melanoma has been considered one of the toughest cancers to treat, with few drug options...until now. The FDA has approved Roche's unique acting drug for melanoma, the deadliest form of skin cancer. Zelboraf (vemurafenib) works by targeting a mutant gene that's found in about half of melanoma patients. This makes two drugs approved that direct confront the deadly disease, a form of skin cancer...
FDA Approval Of Zelboraf™ (vemurafenib) Establishes Oncology Foothold In US For Daiichi Sankyo
8/18/2011
With the US Food and Drug Administration (FDA) approval of Zelboraf™ (vemurafenib), a first-in-class personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test, Daiichi Sankyo prepares to enter the US cancer market with its first oral, targeted anti-cancer therapy...
Blocking Cancer Cell's Energy 'Generator' Could Lead To New Targeted Treatments
8/18/2011
CANCER RESEARCH UK scientists have found that blocking the pathway used by some kidney cancer cells to generate energy can kill the cancer cells, sparing the healthy ones. The research is published in Nature today (Wednesday). Cells need energy to grow and divide...
Blood Vessels Participate In The Eradication Of Tumors
8/18/2011
Breast cancer: for the first time, very specific blood vessels have been discovered in tumors. These vessels facilitate the access of certain white blood cells, known as "killer lymphocytes", into tumor tissues and thus lead to the efficient destruction of tumors...
Flexible-fiber CO2 Laser Proves Safe In Endoscopic Endonasal Transsphenoidal Surgery
8/18/2011
A new study has shown the Flexible-Fiber CO2 laser to safely cut and coagulate during endoscopic assisted transsphenoidal craniotomies (TSC) without the line of sight problems encountered with conventional CO2 lasers. The findings, reported by researchers from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM), appear in the July/August issue of World Neurosurgery...
New Risk Score Spots Patients At High Risk Of Serious Blood Clots
8/18/2011
A new risk prediction tool can identify patients at high risk of serious blood clots who might need preventative treatment, according to a study published on bmj.com. The tool, which can be found at www.qthrombosis...
Five "Mutants" Linked To Prostate Cancer Equals Genetic Breakthrough
8/18/2011
In the process to finally unravel the mysteries of prostate cancer and even develop a blood test that can help doctors plan treatment options in the early stages, five new gene variants, or mutations have been linked to the aggressive and deadly disease. Meet LEPR, CRY1, RNASEL, IL4 and ARVCF...
Vitamin D Confirmed As A Protective Agent Against The Advance Of Colon Cancer
8/18/2011
The indication that vitamin D and its derivatives have a protective effect against various types of cancer is not new. In the field of colon cancer, numerous experimental and epidemiological studies show that vitamin D3 (or cholecalciferol) and some of its derivatives inhibit the growth of cancerous cells...
Radioactive Iodine Being Used More To Treat Thyroid Cancer
8/18/2011
According to a study in the August 17 issue of JAMA, despite uncertainty about the appropriate use of radioactive iodine after surgery for different stages of thyroid cancer, its use has increased between 1990 and 2008 among patients with all tumor sizes and there was wide variation in use of this treatment among hospitals...
Research Scientists Expand Knowledge Of Cell Process Involved In Many Diseases
8/18/2011
As part of a joint research effort with the University of Michigan, scientists from the Florida campus of The Scripps Research Institute have for the first time defined the structure of one of the cell's most basic engines, which is required for cell growth, as it assembles from its components...